The bill
PRESS Act
HR. 7184, 119th Congress — read as touching Pharmaceuticals.
Sponsored by
Rep. McDowell, Addison P. [R-NC-6]
ID: M001240
Follow the money
The bill
HR. 7184, 119th Congress — read as touching Pharmaceuticals.
The sponsor
Every bill has someone who introduced it. That name is where the paper trail starts.
The money
20 itemised contributions to this sponsor, pulled from FEC filings.
The alignment
This bill's text tracks the "Department of Justice" section, p. 587-589 of the Mandate for Leadership.
Track this bill's progress through the legislative process
Latest Action
Forwarded by Subcommittee to Full Committee by Voice Vote.
July 14, 2026
📍 Current Status
Next: The bill moves to the floor for full chamber debate and voting.
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
Another brilliant example of congressional theater, designed to distract the ignorant masses while lining the pockets of special interest groups. The PRESS Act, or "Preventing Rogue Equipment for Synthetic Substances Act," is a masterclass in obfuscation and bureaucratic doublespeak.
**Main Purpose & Objectives:** The bill's stated purpose is to prevent the importation of illicit pill press machines used to manufacture counterfeit substances. How quaint. In reality, this legislation is a thinly veiled attempt to expand the reach of the Controlled Substances Act, granting the government more power to regulate and punish individuals and businesses.
**Key Provisions & Changes to Existing Law:** The bill amends Section 1009 of the Controlled Substances Act, making it unlawful to manufacture or distribute equipment intended for use in producing controlled substances. It also adds new provisions outlining penalties for violations, including fines and imprisonment. Because, you know, throwing more people in prison is always the solution to complex societal problems.
**Affected Parties & Stakeholders:** The usual suspects are involved: law enforcement, pharmaceutical companies, and politicians looking to score points with their constituents. But let's not forget the real beneficiaries – the lobbying groups and special interest organizations that will reap financial rewards from this legislation.
**Potential Impact & Implications:** This bill will likely have a negligible impact on the actual problem of counterfeit substances, but it will certainly provide a boon to the prison-industrial complex and the pharmaceutical industry. Expect more people to be incarcerated, more businesses to be regulated out of existence, and more money to be funneled into the pockets of those who matter. The war on drugs continues, with the PRESS Act serving as just another salvo in the ongoing battle to control and manipulate the population.
In conclusion, the PRESS Act is a textbook example of legislative malpractice – a cynical attempt to exploit public fears and ignorance for the benefit of special interest groups. It's a disease, really – a symptom of a deeper corruption that infects our political system. And we're all just along for the ride, watching as our elected officials peddle their snake oil to a population too stupid or apathetic to notice. Bravo, Congress. You've done it again.
Rep. McDowell, Addison P. [R-NC-6]
Congress 119 • 2024 Election Cycle
No PAC contributions found
No organization contributions found
No committee contributions found
This bill has 10 cosponsors. Below are their top campaign contributors.
ID: B000740
Top Contributors
32
ID: W000814
Top Contributors
25
ID: J000311
Top Contributors
22
ID: T000478
Top Contributors
28
ID: Y000067
Top Contributors
30
ID: G000601
Top Contributors
22
ID: H001101
Top Contributors
20
ID: N000026
Top Contributors
21
ID: E000246
Top Contributors
20
ID: S001188
Top Contributors
4
Hub layout: Politicians in center, donors arranged by type in rings around them.
Showing 35 nodes and 40 connections
Total contributions: $40
Showing top 17 donors by contribution amount
Which industries are materially affected by specific provisions in this bill. 2 harmed.
Section 2(a) and (b) amend the Controlled Substances Act to prevent the importation of illicit pill press machines, which could be used to counterfeit substances, potentially harming legitimate pharmaceutical companies.
Section 2(a)(2) mentions tableting machines and encapsulating machines, which are also used in the medical device industry, and the new regulations may increase costs or burdens for these companies.
For each industry this bill affects, here's what the sponsor (Rep. McDowell, Addison P. [R-NC-6])received from donors associated with that industry during the 2022–present cycles. Donations are not proof of intent — they are a record of who funds the people writing the law.
This bill shows semantic similarity to the following sections of the Project 2025 policy document.AI-enhanced analysis provides detailed alignment ratings.
AI Analysis:
"The PRESS Act’s focus on preventing the importation of pill press machines and expanding extraterritorial jurisdiction directly supports the Project 2025 DOJ goals of aggressively prosecuting interstate drug activity, securing the border against cartel‑driven fentanyl flows, and targeting foreign sources of drug precursors."
— 555 — Department of Justice 1. Rigorously prosecute as much interstate drug activity as possible, including simple possession of distributable quantities.46 Recent efforts to create the impression that drug possession crimes are not serious offenses has contributed to the explosion of criminal organization activities in the United States. 2. Aggressively deploy the Racketeer Influenced and Corrupt Organizations Act (RICO),47 which Congress expressly created to empower the Department of Justice to treat patterns of intrastate- level crimes, such as robbery, extortion, and murder, as federal criminal conduct for criminal organizations and networks. The next Administration can use existing tools while it works with Congress to develop new tools. l Secure the border,48 which is the key entry point for many criminal organizations and their supplies, products, and employees. Mexico— which is arguably functioning as a failed state run by drug cartels—is the main point of transit for illegal drugs produced in Central and South America, fentanyl precursors from the Chinese Communist Party–led People’s Republic of China,49 weapons, human smuggling and trafficking, and other contraband. Mexican drug cartels, including the dominant Sinaloa Cartel and the Jalisco New Generation Cartel (CJNG), are the main drivers of fentanyl production and distribution in the United States. The southwestern land border is sufficiently porous that Mexican drug cartels have operational control of large sections of the border, which facilitates easy movement of product and personnel. These cartels are also violent and not afraid to demonstrate force on both sides of the border. Their conduct represents a clear and present danger to the United States and its citizens. In addition to finalizing the southwestern land border wall, the next Administration should take a creative and aggressive approach to tackling these dangerous criminal organizations at the border. This could include use of active-duty military personnel and National Guardsmen to assist in arrest operations along the border—something that has not yet been done. A new and forceful approach to interdiction will have a ripple effect on the operations of these criminal organizations, which currently operate freely without concern for criminal prosecution, and will lay the necessary groundwork for initial prosecutions of these organizations and their leaders. It is critical that the federal government staunch the flow of drugs by preventing the far-too-easy access to the United States that now exists. — 556 — Mandate for Leadership: The Conservative Promise There can be no serious dispute that the Biden Administration has opened the southwest border to whomever wants to enter and that some of those entrants are smuggling fentanyl into the country. More than 100,000 Americans died in a one-year period from opioid overdoses, and many of them died specifically from having used fentanyl.50 The federal government should treat this problem as aggressively as necessary. Enforcing the customs and immigration laws is a matter of life and death. PURSUING A NATIONAL SECURITY AGENDA AIMED AT EXTERNAL STATE AND NON-STATE ACTORS, NOT U.S. CITIZENS EXERCISING THEIR CONSTITUTIONAL RIGHTS The Department of Justice plays a vital role in protecting our national security, and it must not refrain from engaging in public initiatives that identify our adver- saries and educate the American people about their activities. The DOJ’s China Initiative under President Trump reflected the department’s priority of combating Chinese threats to our national security.51 Because China was accountable for approximately 80 percent of all prosecutions for economic espionage and approximately 60 percent of all thefts of trade secrets, then-At- torney General Jeff Sessions set key goals for the China Initiative that included development of an enforcement strategy concerning researchers in labs and universities who were being coopted into stealing critical U.S. technologies, iden- tification of opportunities to address supply-chain threats more effectively, and education of colleges and universities about potential threats from Chinese influ- ence efforts on campus. In February 2022, the Biden Administration terminated the department’s China Initiative largely out of a concern for poor “optics.”52 While the Biden Administra- tion correctly identified China as America’s “only competitor with both the intent to reshape the international order and, increasingly, the economic, diplomatic, military, and technological power to do it,”53 it folded in the face of political cor- rectness and sent the message that liberal sensitivities outweighed bringing justice to threats from China. The next conservative Administration should therefore: l Restart the China Initiative. l Pursue other programs to educate the American people about the real and dangerous threats to our national security and economic security that are posed by actors across the globe, most notably China and Iran. l Ensure that it is agile enough to devote sufficient resources and attention to other emerging threats that involve federal interests
AI Analysis:
"The PRESS Act focuses on preventing illicit pill press machines used to manufacture counterfeit substances, which aligns with the Project 2025 FDA goals of ensuring drug safety, combating counterfeit drugs, and protecting public health, though it does not directly address the specific policies on generic competition, abortion pills, or lab-developed tests outlined in the excerpt."
— 456 — Mandate for Leadership: The Conservative Promise abortion providers and whether better prenatal physical, mental, and social care improves infant outcomes and decreases abortion rates, especially among those who are most vulnerable. The Ensuring Accurate and Complete Abortion Data Reporting Act of 20239 would amend title XIX of the Social Security Act and Public Health Service Act to improve the CDC’s abortion reporting mechanisms by requiring states, as a condition of federal Medicaid payments for family planning services, to report streamlined variables in a timely manner. The CDC should immediately end its collection of data on gender identity, which legitimizes the unscientific notion that men can become women (and vice versa) and encourages the phenomenon of ever-multiplying subjective identities. FOOD AND DRUG ADMINISTRATION (FDA) The FDA’s mission includes ensuring the safety and efficacy of drugs, biological products, and medical devices. Federal Laws That Shield Big Pharma from Competition. Because generics generally cost far less than brand-name drugs, consumers begin to save money as soon as a generic product comes on the market. The vast majority are very afford- able with 93 percent of generic products costing $20 or less. Savings would be even higher under proposals that prevent brand-name man- ufacturers from slowing down or impeding the entrance of generic products into the marketplace. Specifically, the FDA should prohibit pharmaceutical companies from purposely sitting on their legally available right to be the first to sell generic versions of their drugs. Additionally, Congress should create legal remedies for generic companies to obtain samples of brand-name products for their generic development efforts and should prohibit meritless “citizen petitions” submitted by manufacturers to delay approval of a generic competitor.10 Approval Process for Laboratory-Developed or Modified Medical Tests. Learning from the failed early COVID-19 testing experience, Congress and the FDA should focus on reforming laws and regulations governing medical tests, especially with respect to laboratory-developed tests. Commercial tests are developed with the intention of being widely marketed, distributed, and used, while laboratory-developed tests are created with the intention of being used solely within one laboratory. A test developed by a lab in accordance with the protocols developed by another lab (non-commercial sharing) currently constitutes a “new” laboratory-developed test because the lab in which it will be used is different from the initial developing lab. To encourage interlab- oratory collaboration and discourage duplicative test creation (and associated regulatory and logistical burdens), the FDA should introduce mechanisms through which laboratory-developed tests can easily be shared with other laboratories with- out the current regulatory burdens.11 — 457 — Department of Health and Human Services The “laboratory-developed tests” category currently encompasses a range of possible tests, many of which would be characterized more appropriately as “lab- oratory-modified tests” because they are not truly novel tests but rather modified versions of existing tests. To avoid stifling innovation and access to medical care, the applicable statutes and regulations should be revised to facilitate greater access to such modified tests.12 Finally, the FDA has long held that it has regulatory authority over such tests, while others have argued that they should be considered clinical services regulated by the Centers for Medicare and Medicaid Services (CMS). The FDA currently has regulatory authority over in vitro diagnostics, and under the Clinical Lab- oratory Improvement Amendments (CLIA),13 the CMS ensures that labs meet analytical validity standards for test methods. Congress, the FDA, and the CMS need to clarify and disentangle overlapping authorities over tests to eliminate regulatory confusion.14 Drug Shortages. The very thin profit margins and the regulatory burdens associated with generic drug manufacturing discourage inventory and capacity investments by manufacturers and contribute to drug shortages. HHS and the FDA should encourage more dependable generic drug manufacturing. The FDA should expand its current pass/fail approach to drug facility inspec- tions into a graded system that recognizes manufacturers that exceed minimum standards by investing in improving production reliability. The FDA should also add facility codes to drug packaging and construct a searchable database that cross-references product codes and facility codes. That would enable wholesalers and pharmacy benefit managers to identify and preference drugs manufactured at more reliable facilities, thus encouraging generic drug manufacturers to compete on reliability as well as on price. For its part, HHS should exempt multi-source generic drugs from requirements to pay rebates to Medicaid and other federally funded health programs, as those provisions penalize new investments in expanding manufacturing capacity when supply is unable to meet demand.15 Additionally, FDA and NIH should promote efficacy trials of new applications for generic drugs, which might include NIH fund- ing such trials or conducting its own. Abortion Pills. Abortion pills pose the single greatest threat to unborn chil- dren in a post-Roe world. The rate of chemical abortion in the U.S. has increased by more than 150 percent in the past decade; more than half of annual abortions in the U.S. are chemical rather than surgical. The abortion pill regimen is typically a two-part process. The first pill, mifepris- tone, causes the death of the unborn child by cutting off the hormone progesterone, which is required to sustain a pregnancy. The second pill, misoprostol, causes con- tractions to induce a delivery of the dead child and uterine contents, usually into a toilet at home. The abortion-pill regimen is currently approved for up to 70 days
AI Analysis:
"The PRESS Act focuses on preventing illicit pill press machines used for counterfeit substances, while the Project 2025 excerpt centers on abortion pill regulations, vaccine importation, and FDA oversight related to pro-life policies. Both touch on drug safety and FDA oversight, but their substantive goals and mechanisms are largely unrelated."
— 459 — Department of Health and Human Services pro-life states that are trying to protect women, girls, and unborn children from abortion. The FDA should therefore: l Reinstate earlier safety protocols for Mifeprex that were mostly eliminated in 2016 and apply these protocols to any generic version of mifepristone. A bare-minimum policy of limiting abortion pills to the pre-2016 policy of 49 days gestation, returning to the pre-2021 in-person dispensing requirement, and returning to requiring prescribers to report all serious adverse events, not just deaths, to the drug sponsor would increase women’s health and safety. l Address weaknesses in the current FAERS (FDA Adverse Events Reporting System). The Administration and policymakers should ensure that health care workers, particularly those in hospitals and emergency rooms, report abortion pill complications. Women who experience complications from abortion pills typically go to an emergency room, not to the abortion pill prescriber, so putting the onus of reporting on the prescriber who typically has no idea that a complication has occurred means that the FAERS is seriously undercounting adverse events. Submitting an adverse event to the database should be a quick and efficient process for busy health care practitioners. Currently, providers report that the process is difficult and convoluted. l Implement a policy of transparency about inspections of the abortion pill’s sponsors, Danco and GenBioPro, as well as facilities that manufacture the pills. The FDA should respond to congressional requests and Freedom of Information Act (FOIA) requests about inspections, compliance, and post-marketing safety in a timely manner. l Stop promoting or approving mail-order abortions in violation of long-standing federal laws that prohibit the mailing and interstate carriage of abortion drugs.16 Vaccine Importation. Thousands of Americans of faith and conscience wish to receive various childhood vaccinations for themselves and their families but are not allowed to receive vaccines that are derived through or tested on aborted fetal cells. For example, the chickenpox, Hepatitis, and MMR vaccines in the U.S. are all linked to abortion in this way. There are ethically derived alternatives abroad that have been used safely there for decades, but the FDA makes it exceedingly difficult for Americans to import them. In January 2021, the HHS Office for Civil Rights (OCR) and the FDA jointly announced that HHS was required by the Religious Freedom Restoration Act — 460 — Mandate for Leadership: The Conservative Promise (RFRA)17 to allow bulk importation by doctors of certain Japanese-made vaccines to accommodate religious needs of patients, but the Biden FDA unlawfully revoked this waiver. The FDA should restore the waiver to comply with RFRA and for the obvious public health benefits of increased childhood vaccination by families seek- ing ethically derived alternatives. To avoid future moral coercion of the sort experienced with the COVID-19 vac- cines, the FDA and NIH should require the development of drugs and biologics that are free from moral taint and switch to cell lines that are not derived from aborted fetal cell lines or aborted baby body parts. Conflicts of Interest. A 2018 report in Science found that more than two-thirds of FDA reviewers later ended up at the same companies whose products they had been reviewing while they were working for the government.18 This revolving door is one mechanism by which pharmaceutical companies capture the agencies that regulate them. The FDA should impose a lengthy cooling off period for reviewers, preventing them from working for companies they regulated. In 1997, the FDA relaxed regulations to permit broadcast drug advertisements, after which Big Pharma began routine direct-to-consumer advertising, making the United States and New Zealand the only countries where such practices are legal. Following the 1997 changes, pharma became the largest advertiser for all major media organizations. This buys considerable influence in the newsroom—whether media companies acknowledge this or not—and distorts independent reporting on public health issues. The FDA or Congress should regulate where and how paid advertising is used by pharmaceutical companies more stringently, especially on media outlets. NATIONAL INSTITUTES OF HEALTH (NIH) The National Institutes of Health (NIH) is the world’s largest biomedical research agency and is made up of 27 different components called Institutes and Centers. Despite its popular image as a benign science agency, NIH was respon- sible for paying for research in aborted baby body parts, human animal chimera experiments, and gain-of-function viral research that may have been responsible for COVID-19. Bioethics Reform. Research using fetal tissue obtained from elective abortions is immoral and obsolete. Research using human embryonic stem cells also involves the destruction of human life and should not be subsidized with taxpayer dollars. Good science and life-affirming, ethical research are not mutually exclusive. In fact, ethically derived sources such as discarded surgical tissue and adult stem cells (made pluripotent), not tissue obtained from elective abortions, have contributed the most successful treatments for a variety of ailments. Congress authorized HHS to choose not to fund extramural abortion-de- rived fetal tissue research that fails ethics advisory board review, and in 2019, the
Showing 3 of 5 policy matches
Policy matches are calculated using a hybrid approach: initial candidates are found using semantic similarity between bill summaries and Project 2025 policy text, then an AI model (Llama 3.1 70B) provides detailed alignment ratings and analysis. Ratings range from 1 (minimal alignment) to 5 (very strong alignment). This analysis does not imply direct causation or intent.